References
- Lapins J., Asman B., Gustafsson A., Bergstrom K., Emtestam L. Neutrophil‐related host response in hidradenitis suppurativa – a pilot study of patients with inactive disease. Acta Derm Venereol 2001; 81: 96–9
- Von der Worth J. M., Williams H. C. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2000; 14: 389–92
- Harvath L., Yancey K. B., Katz S. I. Selective inhibition of human neutrophils chemotaxis to N‐formyl‐methionyl‐leucyl‐phenyl‐alanine by sulphones. J Immunol 1986; 137: 1305–11
- Martin W. J., Kachel D. L. Reduction of neutrophil‐mediated injury to pulmonary endothelial cells by dapsone. Am Rev Respir Dis 1985; 131: 544–7
- Hofer T., Itin P. H. Acne inversa: a dapsone sensitive dermatosis. Hautarzt 2001; 52: 989–92
- Collier P. M., Kelly S. E., Wojnarowska F. Linear IgA disease and pregnancy. J Am Acad Dermatol 1994; 30: 407–11
- Kahn G. Dapsone is safe during pregnancy. J Am Acad Dermatol 1985; 13((5 Pt 1))838–9
- Wenelboe P. A randomised controlled trial of topical clindamycin vs systemic tetracycline in hidradenitis suppurativa with special reference to disease assessment. J Am Acad Dermatol 1998; 39: 971–4
- Clemmensen O. J., Mortimer P. S., Dawber R. P. R., Gales M. A., Moore R. A. Medication of hidradenitis suppurativa with androgens. BMJ 1986; 292: 245–8
- Gemert J. P. Long‐results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol 1999; 40: 73–6
- Sullivan T. P., Welsh E., Kerdel F. A., Burdick A. E., Kirsner R. S. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003; 149: 1046–9